Infertility, Male
The inability of the male to effect FERTILIZATION of an OVUM after a specified period of unprotected intercourse. Male sterility is permanent infertility.
Subtype terms (6)
More specific conditions that are subtypes of Infertility, Male in the MeSH hierarchy.
- Aspermia
- Asthenozoospermia
14 drugs (6 approved, 8 experimental)
- Azoospermia
6 drugs (3 approved, 3 experimental)
- Oligospermia
20 drugs (11 approved, 9 experimental)
- Sertoli Cell-Only Syndrome
- Teratozoospermia
6 drugs (3 approved, 3 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (17)
Phase 3 trials (22)
Phase 2 trials (17)
Phase 1 trials (10)
Organizations
Organization Involved with Phase 4 Indications (12)
- Hamad Medical Corporation
- U.O. Chirurgia Andrologica
- Cornell University
- Pacira Pharmaceuticals
- Maccabi Healthcare Services, Israel
- Azienda Ospedaliera Antonio Cardarelli
- Androcenter, Napoli
- Fairhaven Health
- Pusan National University
- Rahem Fertility Center of Zagazig, Egypt
- Assuta Ashdod Hospital
- Memorial Şişli Hospital
Organization Involved with Phase 3 Indications (20)
- Catalysis SL
- University of Roma La Sapienza
- Islamic Azad University of Tabriz
- Shahid Beheshti University of Medical Sciences
- Baylor University
- Hillel Yaffe Medical Center
- Maimonides Medical Center
- Repromed
- Royan Institute
- University of Florence
- University of Padova
- University of Adelaide
- University of Valencia
- University of Copenhagen
- University of Modena and Reggio Emilia
- University of Tabriz
- Istituto Clinico Humanitas - Rozzano (MI), Italy
- Technion University
- University of Halle
- University of Paris
Organization Involved with Phase 2 Indications (13)
- Stem Cells Arabia
- National Institutes of Health (NIH)
- University of Pennsylvania
- Augusta University
- Cairo University
- University of Washington
- University of Oklahoma
- Yale University
- University of California, San Francisco
- University of Colorado, Denver
- Al Azhar University
- Pennsylvania State University
- University of North Carolina at Chapel Hill
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (12)